News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
784,613 Results
Type
Article (59938)
Company Profile (374)
Press Release (724300)
Multimedia
Podcasts (123)
Webinars (18)
Section
Business (222772)
Career Advice (2650)
Deals (38187)
Drug Delivery (120)
Drug Development (86242)
Employer Resources (182)
FDA (17589)
Job Trends (16464)
News (376057)
Policy (36558)
Tag
Academia (2919)
Academic (1)
Accelerated approval (9)
Adcomms (28)
Allergies (104)
Alliances (55235)
ALS (118)
Alzheimer's disease (1532)
Antibody-drug conjugate (ADC) (174)
Approvals (17565)
Artificial intelligence (385)
Autoimmune disease (32)
Automation (18)
Bankruptcy (382)
Best Places to Work (12416)
BIOSECURE Act (21)
Biosimilars (127)
Biotechnology (260)
Bladder cancer (98)
Brain cancer (38)
Breast cancer (383)
Cancer (3023)
Cardiovascular disease (234)
Career advice (2236)
Career pathing (33)
CAR-T (201)
CDC (38)
Cell therapy (552)
Cervical cancer (24)
Clinical research (70569)
Collaboration (1093)
Company closure (3)
Compensation (700)
Complete response letters (28)
COVID-19 (2845)
CRISPR (67)
C-suite (348)
Cystic fibrosis (119)
Data (3067)
Decentralized trials (2)
Denatured (43)
Depression (70)
Diabetes (366)
Diagnostics (6854)
Digital health (26)
Diversity (10)
Diversity, equity & inclusion (47)
Drug discovery (173)
Drug pricing (147)
Drug shortages (34)
Duchenne muscular dystrophy (129)
Earnings (93091)
Editorial (48)
Employer branding (23)
Employer resources (159)
Events (124813)
Executive appointments (897)
FDA (19309)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (996)
Gene editing (145)
Generative AI (38)
Gene therapy (417)
GLP-1 (893)
Government (5008)
Grass and pollen (6)
Guidances (181)
Healthcare (20500)
Huntington's disease (30)
IgA nephropathy (42)
Immunology and inflammation (165)
Immuno-oncology (10)
Indications (40)
Infectious disease (3032)
Inflammatory bowel disease (161)
Inflation Reduction Act (12)
Influenza (67)
Intellectual property (123)
Interviews (452)
IPO (17296)
IRA (53)
Job creations (4475)
Job search strategy (1877)
Kidney cancer (13)
Labor market (52)
Layoffs (557)
Leadership (23)
Legal (9117)
Liver cancer (83)
Lung cancer (421)
Lymphoma (213)
Machine learning (11)
Management (64)
Manufacturing (423)
MASH (95)
Medical device (14620)
Medtech (14625)
Mergers & acquisitions (21628)
Metabolic disorders (927)
Multiple sclerosis (102)
NASH (18)
Neurodegenerative disease (134)
Neuropsychiatric disorders (39)
Neuroscience (2263)
NextGen: Class of 2025 (7299)
Non-profit (4949)
Now hiring (47)
Obesity (474)
Opinion (271)
Ovarian cancer (103)
Pain (112)
Pancreatic cancer (124)
Parkinson's disease (196)
Partnered (23)
Patents (313)
Patient recruitment (169)
Peanut (54)
People (62970)
Pharmaceutical (80)
Pharmacy benefit managers (24)
Phase I (21967)
Phase II (30852)
Phase III (23176)
Pipeline (1670)
Policy (228)
Postmarket research (2970)
Preclinical (9594)
Press Release (72)
Prostate cancer (148)
Psychedelics (41)
Radiopharmaceuticals (275)
Rare diseases (504)
Real estate (6757)
Recruiting (68)
Regulatory (25092)
Reports (52)
Research institute (2597)
Resumes & cover letters (428)
Rett syndrome (9)
RNA editing (10)
RSV (55)
Schizophrenia (95)
Series A (167)
Series B (116)
Service/supplier (18)
Sickle cell disease (67)
Special edition (21)
Spinal muscular atrophy (156)
Sponsored (35)
Startups (4065)
State (2)
Stomach cancer (16)
Supply chain (82)
Tariffs (63)
The Weekly (78)
Vaccines (877)
Venture capital (56)
Weight loss (309)
Women's health (51)
Worklife (17)
Date
Today (77)
Last 7 days (417)
Last 30 days (2029)
Last 365 days (33341)
2025 (17971)
2024 (37247)
2023 (42001)
2022 (53371)
2021 (58155)
2020 (57086)
2019 (50354)
2018 (38250)
2017 (35359)
2016 (35706)
2015 (41751)
2014 (35900)
2013 (31556)
2012 (33691)
2011 (34065)
2010 (32813)
Location
Africa (962)
Alabama (67)
Alaska (7)
Arizona (264)
Arkansas (14)
Asia (45106)
Australia (7552)
California (7659)
Canada (2397)
China (715)
Colorado (335)
Connecticut (341)
Delaware (201)
Europe (100305)
Florida (1138)
Georgia (259)
Hawaii (1)
Idaho (65)
Illinois (706)
India (28)
Indiana (376)
Iowa (17)
Japan (235)
Kansas (114)
Kentucky (31)
Louisiana (15)
Maine (66)
Maryland (1085)
Massachusetts (5812)
Michigan (271)
Minnesota (470)
Mississippi (3)
Missouri (98)
Montana (31)
Nebraska (26)
Nevada (82)
New Hampshire (73)
New Jersey (2148)
New Mexico (30)
New York (2148)
North Carolina (1181)
North Dakota (10)
Northern California (3335)
Ohio (246)
Oklahoma (17)
Oregon (39)
Pennsylvania (1641)
Puerto Rico (18)
Rhode Island (38)
South America (1366)
South Carolina (36)
South Dakota (1)
Southern California (2856)
Tennessee (128)
Texas (1155)
United States (28746)
Utah (228)
Virginia (195)
Washington D.C. (77)
Washington State (666)
West Virginia (4)
Wisconsin (74)
784,613 Results for "inverness medical technology inc acquired by johnson and johnson".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Proteologix, Inc. to be Acquired by Johnson & Johnson
Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, today announced that it has entered into a definitive agreement to be acquired by Johnson & Johnson
May 16, 2024
·
2 min read
Deals
Johnson & Johnson to Acquire Shockwave Medical
Johnson & Johnson and Shockwave Medical, Inc. announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired.
April 5, 2024
·
15 min read
Press Releases
Johnson & Johnson Launches VOLT™ Wrist and Proximal Humerus Plating Systems in the U.S.
June 19, 2025
·
10 min read
Press Releases
Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC
June 3, 2025
·
19 min read
Press Releases
New results for Johnson & Johnson’s bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
June 13, 2025
·
9 min read
Press Releases
Johnson & Johnson’s AKEEGA® (niraparib and abiraterone acetate dual-action tablet) is the first PARP inhibitor combo to show improved efficacy in patients with HRR-mutated mHSPC vs. current standard of care
June 3, 2025
·
11 min read
Press Releases
Johnson & Johnson expands efforts to champion the nursing workforce globally
May 8, 2025
·
6 min read
Press Releases
Johnson & Johnson Launches First and Only Daily Disposable Multifocal Toric Contact Lens - ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM
June 23, 2025
·
8 min read
Press Releases
Johnson & Johnson’s dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma
June 16, 2025
·
9 min read
Press Releases
Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership
April 2, 2025
·
10 min read
1 of 78,462
Next
